Document is current
Any future updates will be listed below
-
Authors
Sherratt-Mayhew, Sam https://orcid.org/0009-0001-6197-3645
Page, Charles https://orcid.org/0009-0007-6687-9045
Lowe, Michael https://orcid.org/0000-0001-5712-3800
Labella Alvarez, Fernando
Mollan, Susan P. https://orcid.org/0000-0002-6314-4437
Berman, Gabriele https://orcid.org/0009-0008-3390-9508
- License Information
-
More Information
Article History
Received: 3 August 2025
Revised: 14 August 2025
Accepted: 2 September 2025
First Online: 19 September 2025
Competing interests
: Susan Mollan reports consultancy fees (Invex Therapeutics); advisory board fees (Ocular therapeutix); speaker fees (Teva); Travel (Abbvie and European Alliance of Associations for Rheumatology); Receipt of equipment (Heidelberg Engineering). Susan Mollan is a section editor at Eye Journal. Authors declare no other financial relationships with any organisations that might have an interest in the submitted work; and no other relationships or activities that could appear to have influenced the submitted work.
